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BACKGROUND: Patients with cancer frequently transition between different types of specialists and across care settings. This study
explored how frequently the surgical and medical oncology care of stage III colon cancer patients occurred across more than 1 hospi-
tal and whether this was associated with mortality and costs. METHODS: This was a retrospective Surveillance, Epidemiology, and
End Results–Medicare cohort study of 9075 stage III colon cancer patients diagnosed between 2000 and 2009 who had received
both surgical and medical oncology care within 1 year of their diagnosis. Patients were assigned to the hospital at which they had
undergone their cancer surgery and to their oncologist’s primary hospital, and then they were characterized according to whether
these hospitals were the same or different. Outcomes included all-cause mortality, subhazards for colon cancer–specific mortality,
and costs of care at 12 months. RESULTS: Thirty-seven percent of the patients received their surgical and medical oncology care from
different hospitals. Rural patients were less likely than urban patients to receive medical oncology care from the same hospital (odds
ratio, 0.62; 95% confidence interval, 0.43-0.90). Care from the same hospital was not associated with reduced all-cause or colon can-
cer–specific mortality but resulted in lower costs (8% of the median cost) at 12 months (dollars saved, $5493; 95% confidence inter-
val, $1799-$9525). CONCLUSIONS: The delivery of surgical and medical oncology care at the same hospital was associated with
lower costs; however, reforms seeking to improve outcomes and lower costs through the integration of complex care will need to
address the significant proportion of patients receiving care at more than 1 hospital. Cancer 2015;121:3316-24. VC 2015 American Can-
cer Society.
KEYWORDS: colon cancer, delivery of health care, health care costs, integrated health care systems, mortality, patient care
management.
INTRODUCTION
Fragmentation of care is a central cause of poor quality and high costs in the United States.1,2 Because of its resource inten-
sity, complexity for patients, and inequities in quality, cancer care has been identified by the Institute of Medicine as a pri-
ority area for addressing care fragmentation.3 One strategy for reducing fragmentation involves improving continuity
during transitions in care, that is, junctures at which a patient’s care switches between providers, settings, or institutions.3,4
Many current health care reforms, including accountable care organizations, seek to create continuity during transitions
by developing integrated networks of providers and institutions to deliver complex care.5
At the same time, more cancer patients are receiving care from high-volume surgeons located at a few high-volume
regional surgical centers.6,7 Patients who travel to a hospital for surgical care while they are receiving oncologic care from a
different local hospital may experience increased fragmentation. In some settings, receiving treatment for an illness from
more than 1 hospital is associated with poorer outcomes and delays in care.8,9
For most cancer care, transitioning between specialists (ie, a surgeon and a oncologist) and settings (ie, inpatient and
outpatient settings) is inevitable. However, it is plausible that patient outcomes and costs may improve when cancer
patients receive 1-hospital care, that is, surgical and oncologic care delivered at the same hospital. One-hospital care may
ease the coordination of follow-up care, decrease barriers to physician communication, and reduce redundancy in care.
The effect of this type of care fragmentation (1-hospital care vs 2-hospital care) on cancer mortality and costs of care is
unknown.
Stage III colon cancer provides an important model for examining fragmentation due to 2-hospital care. Colorectal
cancer is the second most expensive cancer and the third leading cause of cancer mortality in the United States.10
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Furthermore, guidelines for stage III colon cancer recom-
mend timely surgery and adjuvant chemotherapy to
improve survival.11 Because this requires coordination
between 2 separate providers across different settings
(inpatient surgical care and outpatient medical oncology
care) and possibly at different institutions, patients with
stage III colon cancer are particularly vulnerable to care
fragmentation. Indeed, a significant proportion of
patients do not receive guideline-concordant care, and
disparities exist.11
To evaluate the association between care fragmenta-
tion and outcomes for stage III colon cancer, we examined
the associations between 1- and 2-hospital care and overall




We used Surveillance, Epidemiology, and End Results
(SEER)–Medicare files for patients with colon cancer who
were diagnosed between 2000 and 2009. The SEER-
Medicare database is a population-based cancer registry
encompassing approximately 28% of the US population,
and it is linked to claims for approximately 93% of
patients withMedicare.12
Patients with continuous Part A and B Medicare
coverage during the 12 months before and after the diag-
nosis date were eligible for inclusion. Patients were
excluded if they were younger than 66 years, were enrolled
in a health maintenance organization during the 2-year
interval, were diagnosed at autopsy or death, were diag-
nosed with a second cancer within 12 months of the colon
cancer diagnosis, were lacking information for covariates,
were not stage III, or could not be assigned to their sur-
geons, oncologists, and surgical/oncologic hospitals. We
included only patients receiving care at hospitals capable
of providing both surgical and oncologic care (ie, hospitals
that had both medical oncology and surgical claims associ-
ated with them in a given year). The final analytic cohort
consisted of 9075 patients (Fig. 1).
Measures
Outcomes
The primary outcome was all-cause mortality; survival
time was calculated from the date of the colon cancer di-
agnosis to the Medicare date of death or the censor date of
December 31, 2011. Colon cancer–specific mortality was
a secondary outcome; the censor date was December 31,
2009 because the cause of death was not available after
this date. We also examined the total cost of care 12
months after diagnosis, which was calculated with inpa-
tient claims (Medicare Provider Analysis and Review file),
physician fees (Carrier Claims file), and outpatient claims
(Outpatient Statistical Analysis file).
Provider and Hospital Assignment
For surgical care, the operative surgeon was identified as
the patient’s surgeon, and the location of the procedure
was the patient’s surgical hospital. For the 713 patients
(7.9%) who had more than 1 colon cancer surgery, the
assignment of surgical care was based on the first opera-
tion. For oncologic care, we assigned patients to the med-
ical oncologists who billed for the plurality of their visits
in the year following their diagnosis (using Berenson-
Eggers Type of Service codes M1-M6 to identify appro-
priate claims and specialty codes 83 and 90), and then we
designated the hospital at which these oncologists were
most likely to practice.13 In accordance with Bynum
et al’s approach,14 oncologists were assigned to the hospi-
tal at which they billed for the most inpatient care.
Oncologists who did not bill any inpatient claims were
assigned to the hospital to which most of their patients
were admitted. Patients were classified as experiencing 1-
hospital care if they underwent their operation at the hos-
pital to which their oncologist was assigned, and they
were classified as receiving 2-hospital care if the hospitals
were different.
Patient-Level Covariates
Covariates included the following: age, sex, self-reported
Medicare race (black, white, or other), census tract
Figure 1. Flowchart of inclusions and exclusions for the ana-
lytic cohort. CRC indicates colorectal cancer; SEER, Surveil-
lance, Epidemiology, and End Results.
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median household income (in quartiles), year of diagno-
sis, Charlson comorbidity score in the 12 months before
diagnosis, urban/rural residence, and SEER site. Cancer
characteristics included the following: tumor grade,
adequate lymph node resection during surgery (12
lymph nodes), and, for patients diagnosed in 2004 and
onward, cancer substage.15
Physician-Level Covariates
The yearly surgical volume was tabulated with the total
number of all colon cancer patients on whom surgeons
operated in a given year,16 and it was modeled in quartiles
(<2, 2, 3, and >3 cases per year). Similarly, the yearly
panel size of all colon cancer patients attributed to each
medical oncologist was calculated and modeled in quar-
tiles (<2, 2 or 3, 4 or 5, and>5 cases per year).
Hospital-Level Covariates
Hospital characteristics from SEER included National
Cancer Institute–recognized status, academic hospital
status, and for-profit status. We determined the volume
of patients who underwent colon cancer surgery at each
hospital by summing the total number of all colon can-
cer patients between 2000 and 2009. The hospital vol-
ume was analyzed in quartiles with the following
cutoffs: 0 to 111, 112 to 198, 199 to 312, and >312
cases for surgical hospital volumes and <130, 130 to
210, 211 to 320, and >320 cases for oncologic hospital
volumes.16,17
Analysis
Multivariate logistic regression controlling for patient,
provider, and hospital characteristics was performed to
identify characteristics independently associated with 1-
hospital care versus 2-hospital care. A survival analysis for
all-cause mortality was conducted with Cox proportional
hazards models. Fine and Gray’s method for competing
risk regression was used to model mortality due to colon
cancer, and death from other causes was a competing
risk.18 To assess the proportional hazards assumption, we
used a test of a nonzero slope.19
Our cost analyses estimated the difference in costs
between those receiving 1-hospital care and those receiv-
ing 2-hospital care with generalized linear models. Using
modified Park tests to determine the distribution and link
function,20 we modeled nonextreme costs (the bottom
95% of patient costs) with a gamma variance distribution
and extreme costs (top 5%) with an inverse Gaussian var-
iance distribution. All dollar values were inflated to 2009
values with the annual gross domestic product price
index.21
For both survival and cost modeling, we used
propensity-matched, doubly robust regression models.
Propensity scores were modeled as a function of all
patient, physician, and hospital characteristics with
psmatch2 (version 3.0) in Stata.22 Balance was optimized
with 1:1 nearest neighbor matching using a caliper size of
0.01 without replacement. To retain equivalence between
patients with 1-hospital care and patients with 2-hospital
care, hospital characteristics were coded twice (once as the
surgical hospital and once as the oncologic hospital) for
patients receiving 1-hospital care. We corrected for clus-
tering with generalized estimating equations and robust
standard errors. The clustering unit was the medical-
surgical hospital pair at which patients received care.
We performed sensitivity analyses to ensure the
robustness of our findings. First, we modeled all analyses
by controlling for substages in the subcohort of patients
diagnosed in 2004 and onward. Second, we modeled the
total cost of care at 6 months and costs at both 6 and 12
months only for those surviving to each time. Third,
because physician and hospital characteristics may have
been unknown to patients before they received their care,
we reran our propensity models but included only patient
characteristics. Fourth, with known disparities, we tested
for interactions between hospital care and race/ethnicity,
median census tract income, and urban/rural residence.
Fifth, we ran analyses excluding those patients with more
than 1 surgery to avoid a misclassification bias.
Data were analyzed with Stata IC 12.1. Our study
received approval from the institutional review board of
the Johns Hopkins University School of Medicine.
RESULTS
In our cohort of 9075 patients, 37% received 2-hospital
care; that is, they received their medical oncology care
from an oncologist not assigned to their surgical hospital
(Table 1). Patients in rural areas (population< 250,000)
were less likely to receive 1-hospital surgical and medical
oncology care than those in large cities (odds ratio, 0.62;
95% confidence interval [CI], 0.43-0.90). Patients who
received care from higher volume surgeons or from higher
volume surgical hospitals were significantly more likely to
receive 1-hospital care than those who received their surgi-
cal care from lower volume counterparts.
As shown in Figures 2 and 3, there were no signifi-
cant differences in all-cause mortality or colon cancer–
specific mortality between patients receiving 1-hospital
care and patients receiving 2-hospital care. The average
Original Article
3318 Cancer September 15, 2015
TABLE 1. Characteristics of Stage III Colon Cancer Patients Categorized by the Receipt of 1-Hospital Medical
Oncology and Surgical Care Versus 2-Hospital Medical Oncology and Surgical Care
1-Hospital Care
(n5 5758 or 63.45%)
2-Hospital Care
(n5 3317 or 36.55%) P





>65-70 y 941 (16.3) 524 (15.8) .066 Reference
71-75 y 1303 (22.6) 807 (24.3) 0.92 (0.79-1.07)
76-80 y 1473 (25.6) 896 (27.0) 0.92 (0.80-1.07)
81-85 y 1256 (21.8) 677 (20.4) 1.02 (0.88-1.18)
86 y 785 (13.6) 413 (12.5) 1.04 (0.87-1.24)
Female, No. (%) 3282 (57.0) 1886 (56.9) .73 0.99 (0.90-1.09)
Race, No. (%)
White 5003 (86.9) 2778 (84.1) <.001 Reference
Black 427 (7.4) 263 (7.9) 1.07 (0.86-1.33)
Other 328 (5.7) 266 (8.0) 0.82 (0.64-1.05)
Census tract median income, No. (%)
Lowest quartile 1369 (23.8) 1052 (31.7) <.001 Reference
2nd quartile 1345 (23.4) 829 (25.0) 1.04 (0.88-1.22)
3rd quartile 1390 (24.1) 721 (21.7) 1.09 (0.90-1.31)
Highest quartile 1654 (28.7) 715 (21.6) 1.20 (0.97-1.47)
Urban/rural residence, No. (%)
1,000,000 people 3409 (59.2) 1689 (50.9) <.001 Reference
250,000 to <1,000,000 people 1679 (29.2) 880 (26.5) 0.91 (0.66-1.25)
<250,000 people 670 (11.6) 748 (22.6) 0.62 (0.43-0.90)
Charlson comorbidity score, No. (%)
0 3226 (56.0) 1854 (55.9) .89 Reference
1 1435 (24.9) 840 (25.3) 1.02 (0.92-1.14)
2 1097 (19.1) 623 (18.8) 1.07 (0.95-1.21)
Tumor grade, No. (%)
Well differentiated 301 (5.2) 162 (4.9) .099 Reference
Moderately differentiated 3601 (62.5) 2131 (64.2) 0.87 (0.68-1.13)
Poorly differentiated 1716 (29.8) 966 (29.1) 0.85 (0.65-1.12)
Undifferentiated 140 (2.4) 58 (1.8) 1.20 (0.78-1.84)
Adequate lymph node resection, No. (%)
<12 2000 (34.7) 1237 (37.3) .014 Reference
12 3758 (65.3) 2080 (62.7) 0.97 (0.86-1.09)
Substage, No. (%)b
IIIA 368 (10.5) 205 (10.3) .96 Reference
IIIB 1993 (56.8) 1134 (57.2) 0.99 (0.81-1.20)
IIIC 1146 (32.7) 623 (32.4) 0.99 (0.81-1.22)
Provider-level characteristics
Yearly surgical volume, No. (%)
Lowest quartile 1161 (20.2) 901 (27.2) <.001 Reference
2nd quartile 1499 (26.0) 890 (26.8) 1.03 (0.88-1.10)
3rd quartile 1570 (27.3) 779 (23.5) 1.29 (1.14-1.40)
Highest quartile 1528 (26.5) 747 (22.5) 1.38 (1.02-1.77)
Yearly oncologist panel size, No. (%)
Lowest quartile 1432 (24.9) 885 (26.7) <.001 Reference
2nd quartile 1499 (26.0) 767 (23.1) 0.88 (0.69-1.21)
3rd quartile 1401 (24.3) 750 (22.6) 0.93 (0.77-1.15)
Highest quartile 1426 (24.8) 915 (27.6) 0.90 (0.72-1.13)
Hospital-level characteristics
Volume of patients, No. (%)
Surgical hospital <.001 Reference
Lowest quartile 862 (15.0) 1305 (39.3)
2nd quartile 1507 (26.2) 714 (21.5) 2.94 (2.20-3.94)
3rd quartile 1719 (29.9) 656 (19.8) 3.68 (2.59-5.23)
Highest quartile 1670 (29.0) 642 (19.4) 3.99 (2.51-6.33)
Medical oncology hospital <.001 Reference
Lowest quartile 1095 (19.0) 1002 (30.2)
2nd quartile 1529 (26.6) 822 (24.8) 0.98 (0.74-1.30)
3rd quartile 1531 (26.6) 724 (21.8) 0.91 (0.66-1.24)
Highest quartile 1603 (27.8) 769 (23.2) 0.86 (0.59-1.25)
NCI status, No. (%)
Surgical hospital 134 (2.3) 126 (3.8) <.001 0.52 (0.28-0.94)
Medical oncology hospital 134 (2.3) 103 (3.1) .025 1.07 (0.59-1.94)
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follow-up times for all-cause and colon cancer–specific
mortality were 4.3 (total, 38,836 years) and 3.3 years
(total, 29,807 years), respectively. The median unadjusted
cost of care at 12 months was approximately $4500 lower
for patients receiving 1-hospital care ($73,908 vs
$69,406, P5 .001).
Table 2 shows the final propensity score–matched,
doubly robust Cox proportional hazards regression for all-
cause mortality, the competing risks subhazard regression
for colon cancer–specific mortality, and the total cost of
care at 12 months. Appropriate balance was obtained for
covariates (Table 3). Receiving 1-hospital medical oncol-
ogy and surgical care versus 2-hospital care was not associ-
ated with all-cause mortality (hazard ratio, 0.97; 95% CI,
0.92-1.05) or colon cancer–specific mortality (subhazard
ratio, 0.98; 95% CI, 0.89-1.07). However, patients with
nonextreme costs who received 1-hospital care had signifi-
cantly lower total costs than those who received 2-hospital
care (dollars saved, $5493; 95% CI, $1799-$9525). In
particular, we found a statistically significant savings in
inpatient claims (dollars saved, $3076; 95% CI, $520-
$4893) among those receiving 1-hospital care versus 2-
hospital care; this included the inpatient costs of the pri-
mary surgery. There were no statistically significant sav-
ings in physician fees ($523; 95% CI, –$786 to $1702) or
outpatient claims ($1041; 95% CI, –$628 to $2277).
When we examined only those patients diagnosed in
2004 and onward to account for substages (Table 4), the
total cost difference was even greater for 1-hospital care
(dollars saved, $7531; 95% CI, $1783-$13,043).
TABLE 1. Continued
1-Hospital Care
(n5 5758 or 63.45%)
2-Hospital Care
(n5 3317 or 36.55%) P
OR (95% CI) for
Receiving 1-Hospital
Carea
Academic center, No. (%)
Surgical hospital 3202 (55.6) 1578 (47.6) <.001 1.06 (0.79-1.42)
Medical oncology hospital 3202 (55.6) 1833 (55.3) .75 0.83 (0.65-1.06)
For-profit status, No. (%)
Surgical hospital 437 (7.6) 522 (15.7) <.001 0.66 (0.48-0.91)
Medical oncology hospital 437 (7.6) 391 (11.8) <.001 0.98 (0.70-1.37)
Outcome measures
Deaths, No. (%) 3157 (54.8) 1892 (57.0) .041 N/A





Abbreviations: CI, confidence interval; IQR, interquartile range; N/A, not applicable; NCI, National Cancer Institute; OR, odds ratio.
a ORs were fully adjusted for all other variables listed here as well as the diagnosis year and Surveillance, Epidemiology, and End Results site, which are not
shown.
b The sample was restricted to those diagnosed in 2004 and onward (for whom these data were available).
cWilcoxon-Mann-Whitney test.
Figure 2. Kaplan-Meier survival curves for all-cause mortality:
1-hospital care versus 2-hospital care.
Figure 3. Kaplan-Meier survival curves for colon cancer–spe-
cific mortality: 1-hospital care versus 2-hospital care.
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Notably, there were no cost savings among those patients
with the most extreme costs (Table 2).
The results did not significantly change in any of the
sensitivity analyses (Table 4), and all prespecified testing
of statistical interactions terms was nonsignificant.
DISCUSSION
More than one-third of the patients with stage III colon
cancer received their medical oncology care and surgical
care from different hospitals. Although we did not observe
significant differences in either all-cause or colon cancer–
specific mortality related to this type of care fragmenta-
tion, we found significant differences in the 12-month
cost of care. Patients receiving medical oncology care and
surgical care at the same hospital had, on average, an 8%
lower median cost than patients receiving 2-hospital care.
These results raise important concerns regarding attempts
to reduce cancer care fragmentation in the setting of cur-
rent health care reform.
A substantial minority of patients received 2-
hospital surgical and medical oncology care. Notably, ru-
ral residence was associated with receiving 2-hospital med-
ical oncology and surgical care. This finding is consistent
with known barriers to cancer care in rural communities,
namely, limited access to physicians who provide colo-
rectal cancer screening and treatment23-25 and geographic
distance to health care facilities.24,25
Because there is some evidence showing that more
colon cancer patients are receiving surgical care at high-
volume centers (which have been linked to improved
outcomes), we had anticipated that patients would travel
to receive high-volume surgical care but receive their
medical oncology care from a different and potentially
local hospital.6,7,16,17,26 Instead, we found that patients
who received surgery from high-volume surgeons or cen-
ters were more likely to receive 1-hospital care. With evi-
dence suggesting that high-volume surgeons are more
likely to collaborate in decisions about adjuvant chemo-
therapy with oncologists within their institution in com-
parison with lower volume surgeons,27 patients may
prefer to remain at a high-volume cancer center for their
medical oncology care. A deeper understanding of why
patients select certain providers and institutions is still
needed to improve continuity during transitions in spe-
cialist care.
In contrast to our expectations, we did not observe
differences in mortality between patients who received 1-
hospital care or 2-hospital care in our study. Outcomes
other than mortality such as process quality measures,
delays in care, and satisfaction with care have been shown
to vary with care fragmentation and warrant further study
in the setting of 1-hospital cancer care versus 2-hospital
cancer care.8,9 Furthermore, informal connections
between different hospitals, such as collaboration between
providers and the emergence of patient navigators and
care managers, may mitigate the mechanisms through
which 2-hospital care potentially affects patient
outcomes.28,29
We did observe lower costs among patients who
received 1-hospital cancer care, and this suggests that per-
haps less fragmented delivery of complex cancer care helps
to reduce health care costs. Inpatient hospital costs in par-
ticular were significantly lower among those receiving 1-
hospital care. These savings nearly doubled between 6
months and 1 year after the diagnosis, and this possibly
reflects the fact that cost differences may be related to
both early treatment and ongoing care or complications
of early care. Single-hospital care delivery did not, how-
ever, decrease the expenditures of those patients with the
most extreme costs. Further study is required to investi-
gate the extent to which cost differences are driven by the
length of the hospital stay, number of hospitalizations,
TABLE 2. All-Cause and Colon Cancer–Specific Mortality and Costs at 12 Months Associated With 1-Hospital
Care Versus 2-Hospital Care From Propensity Score–Matched, Doubly Robust Models
Hazard Ratio for All-Cause
Mortality (n5 5482)a












(n5 296)a b c
1-hospital care Reference Reference Reference Reference
2-hospital care 0.97 (0.92-1.05) 0.98 (0.89-1.07) $5493 ($1799-$9525) $23,244 (–$100,606 to $132,636)
a Ninety-five percent confidence intervals are shown in parentheses. Estimates are fully adjusted for all patient, provider, and hospital characteristics listed in
Table 1 except for the substage (which is available only for those diagnosed in 2004 and onward).
b All dollar values were inflated to 2009 values with the annual gross domestic product price index.
c The patients with extreme costs were those patients whose costs were within the top 5%.
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preventable complications, duplication of services, or
other factors. Electronic medical records and electronic
referral systems, shared by physicians affiliated with the
same hospital, have been associated with small but signifi-
cant reductions in costs and improvements in timely care
delivery and may have a role in explaining these findings,
but to our knowledge, they have not been tested with
respect to cancer care.30,31
There are limitations to our study. First, a large por-
tion of medical oncology care occurs in outpatient set-
tings, and oncologists may be affiliated with more than 1
hospital; both create challenges when one is trying to
assign patients to hospitals. To test the face validity of our
assignment method, we examined to which hospitals
patients were admitted in the year following their diagno-
sis; 86% of the patients had the plurality of their inpatient
admissions at the assigned oncologic hospital, and 93%
had their admissions at either the assigned oncologic hos-
pital or the assigned surgical hospital. Second, in line with
previous studies,32,33 a substantial proportion of the
patients could not be assigned to a medical oncologist; we
relied on specialty codes to identify physicians who were
medical oncologists, and this could lead to misclassifica-
tion if providers were missing a specialty code or were
identified under an alternate specialty code. Third,
because of concerns regarding the completeness of chemo-
therapy claims after changes in billing codes during the
study period, we did not use the administration of chemo-
therapy to classify physicians as medical oncologists, nor
could we confidently determine how 1-hospital care
affected the timely receipt of chemotherapy. Fourth, some
patients receiving care from 2 different hospitals may be
part of a health system that coordinates care between hos-
pitals. As of 2012, only 26% of registered US hospitals
were part of such an integrated network.34 Failing to
account for these connections between hospitals would
bias our findings toward the null. Fifth, we were unable to










>65-70 y 16.7 15.8 2.5
71-75 y 22.4 23.7 22.8
76-80 y 26.8 26.7 0.6
81-85 y 21.3 20.9 0.8
86 y 12.8 13.1 20.9
Female 58.7 57.2 2.8
Race
White 83.9 84.1 23.5
Black 8.0 7.5 1.8
Other 8.1 7.4 3.0
Census tract income
Lowest quartile 29.2 27.5 3.8
2nd quartile 25.1 24.3 1.9
3rd quartile 21.5 23.5 24.9
Highest quartile 24.2 24.7 21.0
Urban/rural residence




<250,000 people 19.8 17.8 1.8
Charlson comorbidity score
0 55.5 55.3 0.4
1 26.0 25.3 1.1
2 18.5 19.2 21.7
Tumor grade
Well differentiated 4.5 5.0 22.2
Moderately differentiated 64.5 64.2 0.5
Poorly differentiated 28.8 28.9 20.3
Undifferentiated 2.2 1.9 2.6
Adequate lymph node resection 64.2 63.9 0.5
Provider-level characteristics
Yearly surgical volume
Lowest quartile 24.4 23.9 1.4
2nd quartile 24.3 24.9 21.7
3rd quartile 25.9 25.2 1.9
Highest quartile 25.4 26.0 21.6
Yearly oncologist panel size
Lowest quartile 24.3 24.9 21.9
2nd quartile 25.0 25.6 21.5
3rd quartile 24.8 24.2 1.8




Lowest quartile 28.5 27.1 3.4
2nd quartile 25.2 25.9 21.7
3rd quartile 24.3 23.8 1.1
Highest quartile 22.0 23.2 22.8
Medical oncology hospital
Lowest quartile 32.6 30.3 4.3
2nd quartile 24.6 24.2 1.0
3rd quartile 21.9 22.1 20.7
Highest quartile 21.0 23.4 24.5
NCI status
Surgical hospital 4.0 3.9 0.2
Medical oncology hospital 4.0 3.5 3.1
Academic center
Surgical hospital 53.2 53.6 20.8
Medical oncology hospital 53.2 53.7 21.1
For-profit status
Surgical hospital 13.2 11.8 4.7








Overall distribution of all covariates
Before matching — — 8.06
After matching — — 2.75
Abbreviation: NCI, National Cancer Institute.
There was substantial improvement in the balance after we used 1:1 near-
est neighbor matching without replacement and a caliper size of 0.01. The
mean bias was less than 5% across nearly all covariates, and the overall
mean bias for all covariates was reduced to 2.75 from 8.06 after propensity
score matching.
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assess the reasons that patients and their referring pro-
viders select particular surgeons and medical oncologists.
Some patients receiving 2-hospital care may purposefully
seek out specific providers on the basis of reputation,
compatibility, or other personal preferences without
respect to where the providers practice; these patients are
likely to be more active and capable of bridging deficits in
coordination across health care systems. To the extent
that these patients also have better health outcomes, this
may bias our mortality findings toward the null. Although
we used propensity score methods to produce patient
groups resembling each other on observed covariates,
there may still be differences due to unmeasured charac-
teristics. Sixth, our volume measures are based solely on
Medicare data; however, volume measures constructed
with Medicare data are highly correlated with those con-
structed from all-payer data.35 Finally, this study focuses
on patients in fee-for-service Medicare and may not be
generalizable to younger patients or those in preferred
provider organizations, in health maintenance organiza-
tions, or with other types of insurance.
Notwithstanding these limitations, the current work
suggests the potential that integrated delivery systems may
have in reducing cancer costs while underscoring the chal-
lenges of doing so. Although many current health care
delivery reforms, including accountable care organiza-
tions, patient-centered medical homes, and bundled pay-
ments, seek to reduce fragmentation, they do not lock
patients into receiving care through a single hospital or
health system. Efforts to create continuity in complex care
may be hampered by the large proportion of patients who
receive treatment delivered by providers frommore than 1
hospital or system. At the same time, our findings suggest
that costs are lower among patients who receive care from
a single hospital, and this reinforces the potential financial
benefits of delivery models that reduce fragmentation in
complex cancer care.
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Estimates from Table 2 0.97 (0.92-1.05) 0.98 (0.89-1.07) $5493 ($1799-$9525)
Interaction terms with delivery of care
White Reference Reference Reference
Black P5.16 P5.55 P5.23
Other ethnicity P5.59 P5.49 P5.88
Interaction terms with delivery of care
Lowest income quartile Reference Reference Reference
2nd quartile P5.86 P5.17 P5.30
3rd quartile P5.93 P5.26 P5.48
Highest quartile P5.85 P5.21 P5.27
Interaction terms with delivery of care
1,000,000 people Reference Reference Reference
250,000 to <1,000,000 people P5.65 P5.93 P5.58
<250,000 people P5.82 P5.24 P5.52
Adding substage to adjustment modelc 1.02 (0.95-1.10) 0.97 (0.83-1.13) $7531 ($1783-$13,043)
Cost of care at 12 mo for only those
surviving to 12 mo
N/A N/A $5083 ($952-$9066)
Cost of care at 6 mo N/A N/A $2832 ($747-$5470)
Cost of care at 6 mo for only those surviving to 6 mo N/A N/A $2502 ($460-$5124)
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Abbreviation: N/A, not applicable.
a Ninety-five percent confidence intervals are shown in parentheses. Estimates are fully adjusted for all patient, provider, and hospital characteristics listed in
Table 1 (except for the substage unless otherwise noted).
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c The sample was restricted to those diagnosed in 2004 and onward (for whom these data were available).
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